| Literature DB >> 30698991 |
Erhui Jiang1,2, Zhi Xu3, Meng Wang4, Tinglin Yan1,2, Chunming Huang1,2, Xiaocheng Zhou1,2, Qing Liu1,2, Lin Wang1,2, Yang Chen1,2, Hui Wang1,2, Ke Liu1,2,5, Zhe Shao1,2,5, Zhengjun Shang1,2,5.
Abstract
Metabolic reprogramming is a hallmark of cancer. Stromal cells could function as providers of energy metabolites for tumor cells by undergoing the "reverse Warburg effect," but the mechanism has not been fully elucidated. The interaction between the tumoral microvesicles (TMVs) and stroma in the tumor microenvironment plays a critical role in facilitating cancer progression. In this study, we demonstrated a novel mechanism for the TMV-mediated glycometabolic reprogramming of stromal cells. After being incubated with TMVs, normal human gingival fibroblasts exhibited a phenotype switch to cancer-associated fibroblasts and underwent a degradation of caveolin 1 (CAV1) through the ERK1/2-activation pathway. CAV1 degradation further induced the metabolic switch to aerobic glycolysis in the fibroblasts. The microvesicle-activated fibroblasts absorbed more glucose and produced more lactate. The migration and invasion of oral squamous cell carcinoma (OSCC) were promoted after being cocultured with the activated fibroblasts. Fibroblast-cancer cell glycometabolic coupling ring mediated by monocarboxylate transporter (MCT) 4 and MCT1 was then proved in the tumor microenvironment. Results indicated a mechanism for tumor progression by the crosstalk between tumor cells and stromal cells through the reverse Warburg effect via TMVs, thereby identifying potential targets for OSCC prevention and treatment.-Jiang, E., Xu, Z., Wang, M., Yan, T., Huang, C., Zhou, X., Liu, Q., Wang, L., Chen, Y., Wang, H., Liu, K., Shao, Z., Shang, Z. Tumoral microvesicle-activated glycometabolic reprogramming in fibroblasts promotes the progression of oral squamous cell carcinoma.Entities:
Keywords: OSCC; metabolism; reverse Warburg effect; tumor microenvironment; tumor-stroma interaction
Mesh:
Substances:
Year: 2019 PMID: 30698991 DOI: 10.1096/fj.201802226R
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191